Clinicians described the results as “one of the most amazing things I’ve ever seen.” An experimental once-daily oral drug called daraxonrasib has produced unprecedented outcomes in advanced pancreatic cancer, reducing the risk of death by 60% compared to standard chemotherapy.
In the Phase 3 RASolute 302 trial, daraxonrasib, a RAS(ON) multi-selective inhibitor developed by Revolution Medicines, nearly doubled median overall survival from 6.6–6.7 months with chemotherapy to 13.2 months in patients with previously treated metastatic pancreatic ductal adenocarcinoma. The trial, presented as a plenary session at the 2026 ASCO Annual Meeting, triggered a rare standing ovation from oncology experts.
Unlike traditional therapies, daraxonrasib effectively targets multiple KRAS variants and even wild-type RAS, offering broad applicability to the vast majority of pancreatic cancers. The drug was also far better tolerated, with only 1.2% of patients discontinuing treatment due to side effects, compared to 11.2% in the chemotherapy arm.
This represents a major advance for a disease long considered one of the most lethal in oncology. Experts are hailing daraxonrasib as a potential paradigm shift that could transform metastatic pancreatic cancer into a more manageable condition. The FDA has already granted expanded access for eligible patients.
[O’Reilly, E. M., et al. (2026). Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. New England Journal of Medicine. DOI: 10.1056/NEJMoa2605555]